Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International (PIQ) signs an exclusive licence agreement with Sonic Healthcare USA to commercialise PromarkerD in the US
- PromarkerD is a newly developed blood test able to predict a decline in kidney function in type two diabetes
- PIQ says its PromarkerD test is cost-effective, easy to use, and capable of predicting the onset of the disease in patients with diabetes
- This US licence lasts five years and can be extended through mutual agreement
- PIQ shares are up 16.7 per cent and trading at $1.05 at 2:03 pm AEST
Proteomics International (PIQ) has signed an exclusive licence agreement with Sonic Healthcare USA to commercialise its PromarkerD test for diabetic kidney disease (DKD) in the United States.
Under this agreement, Sonic will offer PromarkerD to physicians and healthcare systems through its client engagement teams across the country.
PromarkerD is a newly developed blood test able to predict a decline in kidney function in type two diabetes, with DKD a major complication arising from diabetes.
Proteomics reported an estimated 32 million adults live with diabetes in America and believes its PromarkerD could help identify risks of developing DKD.
Its PromarkerD blood test is considered cost-effective, easy to use, and capable of predicting the onset of the disease in patients with diabetes.
Sonic Healthcare Chief Medical Officer Dr Mohamed Salama said he looked forward to a “fruitful” partnership with Proteomics.
“Our goal of this partnership is to offer PromarkerD as a predictive test that will enable clinicians to identify which patients with type two diabetes are at risk of developing kidney disease,” Dr Salama said.
“The PromarkerD test is an important prognostic tool that will substantially advance diagnostic offerings for the diabetic population.”
The licence with Sonic Healthcare lasts five years and is exclusive to the US but can be extended through mutual agreement and will include commercially agreed royalties based on test sales at a price subject to Proteomics.
PIQ shares were up 16.7 per cent and trading at $1.05 at 2:03 pm AEST.
